Celgene Corporation (CELG) Wednesday announced that the Oncologic Drugs Advisory Committee of the U.S Food and Drug Administration, of the FDA, has set November 8, 2012 as the date for review of the company's New Drug Application for Pomalidomide.
The integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation, announced that it is seeking approval to market pomalidomide in combination with dexamethasone as a potential treatment for patients with relapsed and refractory multiple myeloma that has progressed following at least two prior therapies.
Pomalidomide is not approved in the U.S. for the treatment of multiple myeloma.
For comments and feedback contact: editorial@rttnews.com
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.